133 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27966948	86	Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.	Pharmaceutical
27825552	152	Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.	Takeda Pharmaceutical
27452283	241	Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.	Jadavpur University
26653735	81	Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.	Pfizer
26753813	22	Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.	University of Minnesota
26192023	71	SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.	Florida Atlantic University
25264600	64	Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.	Takeda Pharmaceutical
25265401	38	Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.	Universidad Ceu San Pablo
25192810	66	Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.	Takeda Pharmaceutical
24028490	46	O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.	University of Notre Dame
23246356	52	MMP inhibition by barbiturate homodimers.	Trinity College
17275314	701	Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.	Pomona College
21780776	40	Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.	Wroclaw University of Technology
21413800	56	A one-pot synthesis and biological activity of ageladine A and analogues.	Macquarie University
23149299	50	Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.	Universit£
22540974	67	A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.	University Hospital M£Nster
22175799	22	Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.	Alantos Pharmaceuticals
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University of Florida
18257543	16	Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.	The Hebrew University of Jerusalem
18061445	103	Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).	Bristol-Myers Squibb Research and Development
17956082	86	Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.	University Hospital of The Westf£Lische Wilhelms-Universit£T M£Nster
15713379	40	N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.	Universit£
15139760	110	Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.	The Hebrew University of Jerusalem
12773042	195	Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.	Wyeth Research
11472217	157	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.	Dupont Pharmaceuticals
11472202	143	Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.	TBA
10669559	180	Protease inhibitors: current status and future prospects.	University of Queensland
10579818	162	Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.	Procter and Gamble Pharmaceuticals
10354399	90	Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis.	Hoechst Marion Roussel
9888835	42	Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.	Procter and Gamble Pharmaceuticals
15177439	96	Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.	Pfizer
12824028	75	Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3.	Pfizer
11327577	86	Heterocycle-based MMP inhibitors with P2' substituents.	Procter and Gamble Pharmaceuticals
11378378	34	Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.	Celltech-Chiroscience
22386984	67	In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.	Colosseum Combinatorial Chemistry Centre For Technology (C4T Scarl)
22175825	19	Potent inhibitors of LpxC for the treatment of Gram-negative infections.	Pfizer
22118188	50	A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.	University Hospital M£Nster
22018790	9	Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.	Scripps Florida
22017539	75	Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.	Boehringer Ingelheim Pharmaceuticals
22017477	35	Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.	Instituto Superior T£Cnico
22153340	37	Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD).	Pfizer
20726512	282	Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.	Pfizer
21514700	56	Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.	Universit£
21507637	102	MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.	Pfizer
21493063	67	MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.	Pfizer
20965620	50	Structure-based approach to nanomolar, water soluble matrix metalloproteinases inhibitors (MMPIs).	Protera
20529685	70	MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.	Pfizer
20529684	112	Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.	Pfizer
20005097	58	Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.	Pfizer
19775099	184	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.	Universit£
19725580	93	Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.	Wyeth Research
19606871	124	N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.	Universit£
	39	Mercaptoacyl matrix metalloproteinase inhibitors: The effect of substitution at the mercaptoacyl moiety	TBA
	47	Hydroxamate inhibitors of human gelatinase B (92 kDa)	TBA
	39	Hydroxamate inhibitors of the matrix metallo-proteinases (MMPs) containing novel P1′ heteroatom based modifications	TBA
	40	Novel indolactam-based inhibitors of matrix metalloproteinases	TBA
19053764	101	Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.	Instituto Superior TéCnico
18790648	317	Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.	University of Athens
18364257	16	Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.	The Scripps Research Institute
17719700	39	Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.	Università
17623656	34	Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.	Pfizer
17512742	32	Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.	Université
17276676	112	A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
17267227	12	Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases.	Clermont Auvergne University
17088065	106	alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.	Università
16516466	175	Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16392792	29	Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.	Aventis Pharma Deutschland
16242329	12	N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8.	Università
16153831	87	Synthesis and SAR of highly selective MMP-13 inhibitors.	Wyeth Research
16002291	24	Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.	Pfizer
15953722	56	Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.	Pfizer
15780611	74	Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.	Pfizer
15780605	2	QSAR-by-NMR: quantitative insights into structural determinants for binding affinity by analysis of 1H/15N chemical shift differences in MMP-3 ligands.	Aventis Pharma Deutschland
14711305	26	Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.	University of Athens
12824039	56	Novel inhibitors of procollagen C-proteinase. Part 2: glutamic acid hydroxamates.	Combichem
12408705	73	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.	Bristol-Myers Squibb
11958997	53	Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.	University of Bielefeld
11754593	148	Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.	Abbott Laboratories
11585440	76	Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.	Dupont Pharmaceuticals
11585439	44	Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.	Dupont Pharmaceuticals
11563922	147	Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.	UniversitäT Bielefeld
11327602	58	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.	Roche Research Center
31874775	176	Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors.	"A. Moro" University of Bari
32379447	44	Validating the 1,2-Difluoro Motif As a Hybrid Bioisostere of CF	Westf£Lische Wilhelms-Universit£T M£Nster
10794702	340	Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.	Università
10579851	151	New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.	Astrazeneca
10579815	168	Affinity and selectivity of matrix metalloproteinase inhibitors: a chemometrical study from the perspective of ligands and proteins.	Hoechst Marion Roussel
10522712	109	The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.	British Biotech Pharmaceuticals
10411481	144	Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.	Cea
30954331	54	Proline-based hydroxamates targeting the zinc-dependent deacetylase LpxC: Synthesis, antibacterial properties, and docking studies.	University of Hamburg
10406637	20	Synthesis and identification of conformationally constrained selective MMP inhibitors.	Searle Discovery Research
10360755	17	P1, P2'-linked macrocyclic amine derivatives as matrix metalloproteinase inhibitors.	Dupont Pharmaceuticals
10230616	30	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols.	Searle Discovery Research
9685244	15	Bis-substituted malonic acid hydroxamate derivatives as inhibitors of human neutrophil collagenase (MMP8).	Boehringer Mannheim
9599226	25	Macrocyclic amino carboxylates as selective MMP-8 inhibitors.	Dupont Pharmaceuticals
9464365	30	Design and synthesis of malonic acid-based inhibitors of human neutrophil collagenase (MMP8).	Institut FüR Biochemie
9457244	189	Matrix metalloproteinase inhibitors: a structure-activity study.	Glycomed
30342958	56	Dihydropyrazothiazole derivatives as potential MMP-2/MMP-8 inhibitors for cancer therapy.	Nanjing Agricultural University
30846252	23	Recent developments in the synthesis and applications of phosphinic peptide analogs.	Wroclaw University of Technology
26810711	30	Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography.	Westf£Lische Wilhelms-Universit£T
23899323	87	Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.	University Hospital M£Nster
7629797	73	Inhibition of matrix metalloproteinases by hydroxamates containing heteroatom-based modifications of the P1' group.	Sterling Winthrop Pharmaceuticals Research Division
30212201	17	Validation of Matrix Metalloproteinase-9 (MMP-9) as a Novel Target for Treatment of Diabetic Foot Ulcers in Humans and Discovery of a Potent and Selective Small-Molecule MMP-9 Inhibitor That Accelerates Healing.	University of Notre Dame
28756264	93	Discovery of dehydroabietic acid sulfonamide based derivatives as selective matrix metalloproteinases inactivators that inhibit cell migration and proliferation.	Southeast University
28818461	67	Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis.	Nestl�
30249495	241	Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.	Graz University of Technology
30034605	15	In Search of Selectivity in Inhibition of ADAM10.	University of Notre Dame
29028530	48	A pentanoic acid derivative targeting matrix metalloproteinase-2 (MMP-2) induces apoptosis in a chronic myeloid leukemia cell line.	Jadavpur University
28626528	10	Exploitation of Conformational Dynamics in Imparting Selective Inhibition for Related Matrix Metalloproteinases.	University of Notre Dame
28850227	85	Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.	St. John'S University
28653849	67	Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.	Scripps Florida
21524149	13	Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands.	Suven Life Sciences
16206837	9	Tyrosinase inhibition: conformational analysis based studies on molecular dynamics calculations of bipiperidine based inhibitors.	University of Karachi
8632342	110	Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences.	Eli Lilly
7965765	14	Cloning and pharmacologic characterization of a thromboxane A2 receptor from K562 (human chronic myelogenous leukemia) cells.	University of Cincinnati
7651361	32	Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain.	Georgetown University
7515823	54	Actions of phenylglycine analogs at subtypes of the metabotropic glutamate receptor family.	Novo Nordisk
7509389	8	Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.	Fujisawa Pharmaceutical
19462975	18	Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.	Chemical Genomics Centre of The Max Planck Society
17034127	45	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.	University of Newcastle Upon Tyne
19267461	53	Novel tricyclic inhibitors of IkappaB kinase.	Bristol-Myers Squibb